Literature DB >> 19960492

Ethnic differences in antidepressant response: a prospective multi-site clinical trial.

Ira M Lesser1, Hector F Myers, Keh-Ming Lin, Consuelo Bingham Mira, Nataria T Joseph, Natasha T Olmos, Jonathan Schettino, Russell E Poland.   

Abstract

BACKGROUND: Although depression is a highly prevalent condition that occurs in all ethnic groups, the influence of ethnicity on treatment response still remains unclear.
METHODS: A prospective 8-week, open-label clinical trial comparing the efficacy and side effects of citalopram (CIT) with dose escalation (20-60 mg/day) was performed in African-Americans and Caucasians with nonpsychotic major depression. The intent-to-treat sample consisted of 301 participants (169 African-Americans and 132 Caucasians).
RESULTS: Although African-Americans were more socially disadvantaged and had a more severe depression, outcomes between the groups were similar. Remission rates were approximately 50% in both groups and about 2/3 of participants met response criteria. Retention was greater than 75% in both groups, with no differences in dropout rate. There were no differences in the number of completers, number of visits made, final dose of CIT, or in side effect profiles.
CONCLUSIONS: These results confirm the growing body of evidence, including recent studies using measurement-based care, that patients from minority groups have outcomes that are similar to those of Caucasians. The provision of measurement-based care and encouragement of patient participation can reduce ethnic differences in response to treatment for depression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19960492      PMCID: PMC3113513          DOI: 10.1002/da.20619

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  32 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial.

Authors:  Mark Zimmerman; Iwona Chelminski; Michael A Posternak
Journal:  Am J Psychiatry       Date:  2005-07       Impact factor: 18.112

Review 4.  Treating minority patients with depression and anxiety: what does the evidence tell us?

Authors:  Trevor J Schraufnagel; Amy W Wagner; Jeanne Miranda; Peter P Roy-Byrne
Journal:  Gen Hosp Psychiatry       Date:  2006 Jan-Feb       Impact factor: 3.238

5.  Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis.

Authors:  Peter P Roy-Byrne; Philip Perera; Cornelius D Pitts; Jacquie A Christi
Journal:  J Clin Psychiatry       Date:  2005-10       Impact factor: 4.384

6.  Improving depression care for older, minority patients in primary care.

Authors:  Patricia A Areán; Liat Ayalon; Enid Hunkeler; Elizabeth H B Lin; Lingqi Tang; Linda Harpole; Hugh Hendrie; John W Williams; Jürgen Unützer
Journal:  Med Care       Date:  2005-04       Impact factor: 2.983

7.  Effectiveness of treatments for major depression in primary medical care practice: a post hoc analysis of outcomes for African American and white patients.

Authors:  C Brown; H C Schulberg; D Sacco; J M Perel; P R Houck
Journal:  J Affect Disord       Date:  1999-05       Impact factor: 4.839

8.  Disparities in depression treatment for Latinos and site of care.

Authors:  Isabel T Lagomasino; Megan Dwight-Johnson; Jeanne Miranda; Lily Zhang; Diana Liao; Naihua Duan; Kenneth B Wells
Journal:  Psychiatr Serv       Date:  2005-12       Impact factor: 3.084

9.  Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.

Authors:  Rahn K Bailey; Craig H Mallinckrodt; Madelaine M Wohlreich; John G Watkin; John M Plewes
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

10.  Disparities in the adequacy of depression treatment in the United States.

Authors:  Jeffrey S Harman; Mark J Edlund; John C Fortney
Journal:  Psychiatr Serv       Date:  2004-12       Impact factor: 3.084

View more
  12 in total

1.  Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial.

Authors:  Charles A Hall; Kevin M Simon; Eric J Lenze; Mary Amanda Dew; Amy Begley; Meryl A Butters; Daniel M Blumberger; Jacqueline A Stack; Benoit Mulsant; Charles F Reynolds
Journal:  Psychiatr Serv       Date:  2015-08-17       Impact factor: 3.084

2.  Religiosity and treatment response to antidepressant medication: A prospective multi-site clinical trial.

Authors:  Jonathan R Schettino; Natasha T Olmos; Hector F Myers; Nataria T Joseph; Russell E Poland; Ira M Lesser
Journal:  Ment Health Relig Cult       Date:  2011-06-13

3.  Support and undermining in interpersonal relationships are associated with symptom improvement in a trial of antidepressant medication.

Authors:  Nataria T Joseph; Hector F Myers; Jonathan R Schettino; Natasha T Olmos; Consuelo Bingham-Mira; Ira M Lesser; Russell E Poland
Journal:  Psychiatry       Date:  2011       Impact factor: 2.458

4.  Economic inequalities in the effectiveness of a primary care intervention for depression and suicidal ideation.

Authors:  Stephen E Gilman; Garrett M Fitzmaurice; Martha L Bruce; Thomas Ten Have; M Maria Glymour; Hannah Carliner; George S Alexopoulos; Benoit H Mulsant; Charles F Reynolds; Alex Cohen
Journal:  Epidemiology       Date:  2013-01       Impact factor: 4.822

5.  Racial differences in adherence and response to combined treatment for full and subthreshold post-traumatic stress disorder and alcohol use disorders: A secondary analysis.

Authors:  Lesia M Ruglass; Annelisa Pedersen; Soumia Cheref; Mei-Chen Hu; Denise A Hien
Journal:  J Ethn Subst Abuse       Date:  2015-09-30       Impact factor: 1.507

6.  Race, genetic ancestry and response to antidepressant treatment for major depression.

Authors:  Eleanor Murphy; Liping Hou; Brion S Maher; Girma Woldehawariat; Layla Kassem; Nirmala Akula; Gonzalo Laje; Francis J McMahon
Journal:  Neuropsychopharmacology       Date:  2013-07-05       Impact factor: 7.853

7.  Differences in treatment attitudes between depressed African-American and Caucasian veterans in primary care.

Authors:  John Kasckow; Erin Ingram; Charlotte Brown; James D Tew; Kyaien O Conner; Jennifer Q Morse; Gretchen L Haas; Charles F Reynolds; David W Oslin
Journal:  Psychiatr Serv       Date:  2011-04       Impact factor: 3.084

8.  Open-label, randomized, parallel-group controlled clinical trial of massage for treatment of depression in HIV-infected subjects.

Authors:  Russell E Poland; Lev Gertsik; Joya T Favreau; Shawnee I Smith; James M Mirocha; Uma Rao; Eric S Daar
Journal:  J Altern Complement Med       Date:  2012-10-25       Impact factor: 2.579

Review 9.  Late-life depression in older African Americans: a comprehensive review of epidemiological and clinical data.

Authors:  Yolonda R Pickett; Kisha N Bazelais; Martha L Bruce
Journal:  Int J Geriatr Psychiatry       Date:  2012-12-07       Impact factor: 3.485

10.  Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression.

Authors:  Russell E Poland; Ira M Lesser; Yu-Jui Yvonne Wan; Lev Gertsik; Jie Yao; Leslie J Raffel; Keh-Ming Lin; Hector F Myers
Journal:  Life Sci       Date:  2013-04-03       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.